ASX ANNOUNCEMENT 21 April 2022

Cynata Advances Clinical Trial in Diabetic Foot Ulcers

Melbourne, Australia; 21 April 2022: Cynata Therapeutics Limited (ASX: **"CYP"** or **"Cynata"**), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce enrolment of initial patients in a clinical trial of CYP-006TK as a potential treatment for diabetic foot ulcers (DFU). Subjects are now being followed as planned for the 4-week treatment period out to the conclusion of the study at 24 weeks.

As advised in an announcement dated 22 December 2021, the Phase I trial (protocol number CYP-DFU-P1-01) aims to recruit 30 adult patients with DFU who will be randomly assigned to receive CYP-006TK or standard care of treatment. CYP-006TK is a novel polymer-coated silicon wound dressing seeded with Cymerus™ mesenchymal stem cells (MSCs) to facilitate topical application to the wound. Cynata has exclusively licensed the dressing technology from leading manufacturer of innovative biomedical coatings, TekCyte Limited.

Dr Jolanta Airey, Cynata's Chief Medical Officer, said:
"We are pleased with enrolment of subjects following the commencement of the trial in late December. COVID-19-related changes to patient management at the study sites, initiated shortly after the trial opened, posed a significant number of unforeseen challenges which had a serious impact on enrolment rates. Fortunately, these challenges have now been addressed. Additionally, we have implemented a number of strategies, such as widening recruitment criteria, intended to accelerate recruitment of subjects. We continue to work closely with Professor Fitridge and his team at the Central Adelaide Local Health Network to ensure we meet current expectations to complete the trial later this year."

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, laurenmaree@live.com.au

About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical trial in GvHD is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase 3), respiratory failure and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.